Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
FAK inhibitors in cancer, a patent review – an update on progress37
Malaria transmission blocking compounds: a patent review37
Recent developments of agents targeting Vibrio cholerae : patents and literature data37
The role of patent analysis in target selection36
Update on mGlu4 modulator patents: 2017 to present34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)33
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)29
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review24
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)22
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)21
Inhibition of GTPase KRAS G12D : a review of patent literature20
PDE1 inhibitors: a review of the recent patent literature (2008-present)20
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201320
Antiprotozoal drugs: challenges and opportunities19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)18
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review18
Small-molecule RNA ligands: a patent review (2018–2024)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)16
An updated patent review of MALT1 inhibitors (2021–present)16
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent review of IDH1 inhibitors (2018-present)15
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature14
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders14
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)14
Dopamine D3 receptor ligands: a patent review (2014–2020)13
A patent and literature review of CDK12 inhibitors13
Biofilm and bacterial membrane vesicles: recent advances13
Antimalarial drugs: what’s new in the patents?13
Are patents important indicators of innovation for Chagas disease treatment?12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
An updated patent review of EZH2 inhibitors (2024–present)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
The patent review of the biological activity of tropane containing compounds11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
Correction10
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)9
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)9
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)9
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages9
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)9
0.091217994689941